Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen to launch US Eylea biosimilar
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
Legal win leads Amgen to at-risk launch of Eylea biosimilar
Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of Appeals for the Federal Circuit, which prompted the company to say it would launch "as quickly as possible to help expand access to affordable and effective treatment."
Amgen plans launch of Eylea biosimilar after court ruling
With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as litigation continues.
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App
District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar
On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the
FiercePharma
1d
Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet
While
Regeneron
may have lost its latest bid to block the launch of
Amgen
’s Eylea biosimilar Pavblu, the New York-based ...
STAT
1d
Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more
Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...
4h
Regeneron: Buy Rating Reaffirmed Amid Eylea Biosimilar Challenge and Pipeline Strength
J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.
Seeking Alpha
1mon
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
Leerink Partners downgraded while Truist defended
Regeneron
(NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against
Amgen
(NASDAQ:AMGN) biosimilar for its ...
7d
Regeneron price target lowered to $1,137 from $1,200 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $1,137 from $1,200 and keeps a Buy rating on the shares after ...
1d
Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback